ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.96
-0.04 (-0.44%)
At close: Mar 5, 2026, 4:00 PM EST
8.93
-0.03 (-0.33%)
After-hours: Mar 5, 2026, 4:33 PM EST
ImmunityBio Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ImmunityBio stock have an average target of 12.5, with a low estimate of 7.00 and a high estimate of 23. The average target predicts an increase of 39.51% from the current stock price of 8.96.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ImmunityBio stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $7 → $12 | Buy | Reiterates | $7 → $12 | +33.93% | Mar 4, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $15 | Strong Buy | Maintains | $10 → $15 | +67.41% | Feb 23, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +156.70% | Feb 23, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +167.86% | Feb 19, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +167.86% | Feb 17, 2026 |
Financial Forecast
Revenue This Year
213.63M
from 113.29M
Increased by 88.57%
Revenue Next Year
527.62M
from 213.63M
Increased by 146.98%
EPS This Year
-0.30
from -0.38
EPS Next Year
-0.07
from -0.30
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 268.9M | 820.7M | |||
| Avg | 213.6M | 527.6M | |||
| Low | 176.4M | 271.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 137.4% | 284.2% | |||
| Avg | 88.6% | 147.0% | |||
| Low | 55.7% | 26.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.25 | 0.16 | |||
| Avg | -0.30 | -0.07 | |||
| Low | -0.36 | -0.25 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.